Guidelines for standard preclinical experiments in the mouse model of myasthenia gravis induced by acetylcholine receptor immunization

Experimental Neurology

Volumn 270, Issue , 2015, Pages 11-17

  Tuzun, Erdem ^a   Berrih Aknin, Sonia ^b,c,d,e   Brenner, Talma ^f   Kusner, Linda L ^g   Le Panse, Rozen ^b,c,d,e   Yang, Huan ^h   Tzartos, Socrates ⁱ   Christadoss, Premkumar ^j  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Sorbonne Université   (France)

^c CNRS   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e AIM   (France)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^g GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^h CENTRAL SOUTH UNIVERSITY   (China)

ⁱ UNIVERSITY OF PATRAS   (Greece)

^j University of Texas Medical Branch School of Medicine   (United States)

more..

Author keywords

Experimental animal model; Myasthenia gravis; Pre clinical experiments; Standard operating procedures

Indexed keywords

ANALGESIC AGENT; BUNGAROTOXIN; BUPRENORPHINE; CHOLINERGIC RECEPTOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C9; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; PROBIOTIC AGENT; STEROID; AUTOANTIBODY;

AGE; ANIMAL CARE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; BINDING SITE; BODY WEIGHT; CIRCADIAN RHYTHM; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FOOD; GENETIC VARIABILITY; GRIP STRENGTH; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOPATHOGENESIS; INFANT; LIGHT DARK CYCLE; LYMPHOCYTE PROLIFERATION; MICROBIAL ACTIVITY; MOTIVATION; MOUSE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PAIN; POWER ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; SEX; STRESS; WEIGHT REDUCTION; ANIMAL; IMMUNOLOGY; PROCEDURES; STANDARDS;

ANIMALS; AUTOANTIBODIES; GUIDELINES AS TOPIC; IMMUNIZATION; MICE; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RECEPTORS, CHOLINERGIC;

EID: 84939426065     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2015.02.009     Document Type: Article

References (38)

1. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis. 2007, 26:1-13.
2. Brandtzaeg P. The gut as communicator between environment and host: immunological consequences. Eur. J. Pharmacol. 2011, 668:S16-S32.
3. Cavalcante P., Cufi P., Mantegazza R., Berrih-Aknin S., Bernasconi P., Le Panse R. Etiology of myasthenia gravis: innate immunity signature in pathological thymus. Autoimmun. Rev. 2013, 12:863-874.
4. Chae C.S., Kwon H.K., Hwang J.S., Kim J.E., Im S.H. Prophylactic effect of probiotics on the development of experimental autoimmune myasthenia gravis. PLoS One 2012, 7:e52119.
5. Christadoss P., Poussin M., Deng C. Animal models of myasthenia gravis. Clin. Immunol. 2000, 94:75-87.
6. Curtis A.M., Bellet M.M., Sassone-Corsi P., O'Neill L.A. Circadian clock proteins and immunity. Immunity 2014, 40:178-186.
7. De la Fuente M., Gimenez-Llort L. Models of aging of neuroimmunomodulation: strategies for its improvement. Neuroimmunomodulation 2010, 17:213-216.
8. Dell R.B., Holleran S., Ramakrishnan R. Sample size determination. ILAR J. 2002, 43:207-213.
9. Delpy L., Douin-Echinard V., Garidou L., Bruand C., Saoudi A., Guéry J.C. Estrogen enhances susceptibility to experimental autoimmune myasthenia gravis by promoting type 1-polarized immune responses. J. Immunol. 2005, 175:5050-5057.
10. Deng C., Goluszko E., Tüzün E., Yang H., Christadoss P. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J. Immunol. 2002, 169:1077-1083.
11. Engel A.G., Tsujihata M., Lindstrom J.M., Lennon V.A. The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study. Ann. N. Y. Acad. Sci. 1976, 274:60-79.
12. Gertel-Lapter S., Mizrachi K., Berrih-Aknin S., Fuchs S., Souroujon M.C. Impairment of regulatory T cells in myasthenia gravis: studies in an experimental model. Autoimmun. Rev. 2013, 12:894-903.
13. Gurfein B.T., Davidenko O., Premenko-Lanier M., Milush J.M., Acree M., Dallman M.F., Touma C., Palme R., York V.A., Fromentin G., Darcel N., Nixon D.F., Hecht F.M. Environmental enrichment alters splenic immune cell composition and enhances secondary influenza vaccine responses in mice. Mol. Med. 2014, 20:179-190.
14. Hübner C., Lehr H.A., Bodlaj R., Finckh B., Oexle K., Marklund S.L., Freudenberg K., Kontush A., Speer A., Terwolbeck K., Voit T., Kohlschütter A. Wheat kernel ingestion protects from progression of muscle weakness in mdx mice, an animal model of Duchenne muscular dystrophy. Pediatr. Res. 1996, 40:444-449.
15. Huda R., Tüzün E., Christadoss P. Complement C2 siRNA mediated therapy of myasthenia gravis in mice. J. Autoimmun. 2013, 42:94-104.
16. Jayawant S., Parr J., Vincent A. Autoimmune myasthenia gravis. Handb. Clin. Neurol. 2013, 113:1465-1468.
17. Karachunski P.I., Ostlie N.S., Monfardini C., Conti-Fine B.M. Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. J. Immunol. 2000, 164:5236-5244.
18. Kilkenny C., Browne W.J., Cuthill I.C., Emerson M., Altman D.G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010, 8:e1000412.
19. Kusner L.L., Kaminski H.J. The role of complement in experimental autoimmune myasthenia gravis. Ann. N. Y. Acad. Sci. 2012, 1274:127-132.
20. Lindstrom J.M., Einarson B.L., Lennon V.A., Seybold M.E. Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis. J. Exp. Med. 1976, 144:726-738.
21. Liu S., Zhen G., Meloni B.P., Campbell K., Winn H.R. Rodent stroke model guidelines for preclinical stroke trials. J. Exp. Stroke Transl. Med. 2009, 2:2-27. (1st edition).
22. Malhotra N., Kang J. SMAD regulatory networks construct a balanced immune system. Immunology 2013, 139:1-10.
23. McLennan I.S., Taylor-Jeffs J. The use of sodium lamps to brightly illuminate mouse houses during their dark phases. Lab. Anim. 2004, 38:384-392.
24. Mercado-López X., Cotter C.R., Kim W.K., Sun Y., Muñoz L., Tapia K., López C.B. Highly immunostimulatory RNA derived from a Sendai virus defective viral genome. Vaccine 2013, 31:5713-5721.
25. Qi H., Li J., Allman W., Saini S.S., Tüzün E., Wu X., Estes D.M., Christadoss P. Genetic deficiency of estrogen receptor alpha fails to influence experimental autoimmune myasthenia gravis pathogenesis. J. Neuroimmunol. 2011, 234:165-167.
26. Raverdeau M., Mills K.H. Modulation of T cell and innate immune responses by retinoic acid. J. Immunol. 2014, 192:2953-2958.
27. Swenson J., Olgun S., Radjavi A., Kaur T., Reilly C.M. Clinical efficacy of buprenorphine to minimize distress in MRL/lpr mice. Eur. J. Pharmacol. 2007, 567:67-76.
28. Sztainberg Y., Chen A. An environmental enrichment model for mice. Nat. Protoc. 2010, 5:1535-1539.
29. Taniguchi T., Suzuki T., Miake S., Nomoto K., Hashimoto K., Goda A., Takeya K. Difference in antibody production to hererologus erythrocytes in conventional, specific-pathogen-free (SPF), germfree and antigen-free mice. Microbiol. Immunol. 1978, 22:793-802.
30. Tüzün E., Christadoss P. Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun. Rev. 2013, 12:904-911.
31. Tüzün E., Scott B.G., Yang H., Wu B., Goluszko E., Guigneaux M., Higgs S., Christadoss P. Circulating immune complexes augment severity of antibody-mediated myasthenia gravis in hypogammaglobulinemic RIIIS/J mice. J. Immunol. 2004, 172:5743-5752.
32. Tüzün E., Li J., Saini S.S., Yang H., Christadoss P. Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. J. Neuroimmunol. 2007, 182:167-176.
33. Tüzün E., Huda R., Christadoss P. Complement and cytokine based therapeutic strategies in myasthenia gravis. J. Autoimmun. 2011, 37:136-143.
34. Valdez G., Tapia J.C., Kang H., Clemenson G.D., Gage F.H., Lichtman J.W., Sanes J.R. Attenuation of age-related changes in mouse neuromuscular synapses by caloric restriction and exercise. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14863-14868.
35. Willmann R., De Luca A., Benatar M., Grounds M., Dubach J., Raymackers J.M., Nagaraju K., TREAT-NMD Neuromuscular Network Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice. Neuromuscul. Disord. 2012, 22:43-49.
36. Wu B., Goluszko E., Huda R., Tüzün E., Christadoss P. Experimental autoimmune myasthenia gravis in the mouse. Curr. Protoc. Immunol. 2013, 1-26. (Unit 15.8).
37. Yang H., Tüzün E., Alagappan D., Yu X., Scott B.G., Ischenko A., Christadoss P. IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1. J. Immunol. 2005, 175:2018-2025.
38. Yang H., Wu B., Tüzün E., Saini S.S., Li J., Allman W., Higgs S., Xiao T.L., Christadoss P. A new mouse model of autoimmune ocular myasthenia gravis. Invest. Ophthalmol. Vis. Sci. 2007, 48:5101-5111.